These findings add novel insights into the interconnectedness of RAS/MAPK pathway mutations with cancer, and the still debated cancer predisposition of patients diagnosed with RASopathies and, specifically, PTPN11 variants.26 This evidence concerns the gene PTPN11 and cancer.